Cargando…
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
BACKGROUND: The severe acute respiratory syndrome (SARS) virus is a member of the Coronaviridae (CoV) family that first appeared in the Guangdong Province of China in 2002 and was recognized as an emerging infectious disease in March 2003. Over 8000 cases and 900 deaths occurred during the epidemic....
Autores principales: | Martin, Julie E., Louder, Mark K., Holman, LaSonji A., Gordon, Ingelise J., Enama, Mary E., Larkin, Brenda D., Andrews, Charla A., Vogel, Leatrice, Koup, Richard A., Roederer, Mario, Bailer, Robert T., Gomez, Phillip L., Nason, Martha, Mascola, John R., Nabel, Gary J., Graham, Barney S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612543/ https://www.ncbi.nlm.nih.gov/pubmed/18824060 http://dx.doi.org/10.1016/j.vaccine.2008.09.026 |
Ejemplares similares
-
Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014) -
DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013) -
Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010) -
Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015) -
P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)